Melbourne, Australia 29 November 2021 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic viral immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types is pleased to provide a replay of its presentation from the NWR Virtual Healthcare Day.
